School of Health Sciences, and State Key Laboratory of Virology, Wuhan University, Wuhan 430071, China.
Fudan University School of Medicine, Shanghai 200032, China.
Viruses. 2018 Nov 30;10(12):680. doi: 10.3390/v10120680.
Since emerging in 2012, Middle East Respiratory Syndrome Coronavirus (MERS-CoV) has been a global public health threat with a high fatality rate and worldwide distribution. There are no approved vaccines or therapies for MERS until now. Passive immunotherapy with neutralizing monoclonal antibodies (mAbs) is an effective prophylactic and therapeutic reagent against emerging viruses. In this article, we review current advances in neutralizing mAbs against MERS-CoV. The receptor-binding domain (RBD) in the spike protein of MERS-CoV is a major target, and mouse, camel, or human-derived neutralizing mAbs targeting RBD have been developed. A major problem with neutralizing mAb therapy is mutant escape under selective pressure, which can be solved by combination of neutralizing mAbs targeting different epitopes. Neutralizing mAbs are currently under preclinical evaluation, and they are promising candidate therapeutic agents against MERS-CoV infection.
自 2012 年出现以来，中东呼吸综合征冠状病毒（MERS-CoV）一直是一种具有高死亡率和全球分布的全球公共卫生威胁。到目前为止，还没有针对 MERS 的批准疫苗或治疗方法。针对新兴病毒的被动免疫疗法，即中和单克隆抗体（mAbs），是一种有效的预防和治疗试剂。在本文中，我们综述了针对 MERS-CoV 的中和 mAbs 的最新进展。MERS-CoV 刺突蛋白中的受体结合域（RBD）是主要靶点，已经开发出针对 RBD 的鼠、骆驼或人源中和 mAbs。中和 mAb 治疗的一个主要问题是在选择压力下的突变逃逸，通过针对不同表位的中和 mAb 联合可以解决这个问题。中和 mAbs 目前正在进行临床前评估，它们是针对 MERS-CoV 感染有希望的候选治疗药物。
